Sheryl A. McCarthy

1.8k total citations
14 papers, 1.4k citations indexed

About

Sheryl A. McCarthy is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Sheryl A. McCarthy has authored 14 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Pharmacology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Sheryl A. McCarthy's work include Phosphodiesterase function and regulation (9 papers), Receptor Mechanisms and Signaling (7 papers) and Cholinesterase and Neurodegenerative Diseases (7 papers). Sheryl A. McCarthy is often cited by papers focused on Phosphodiesterase function and regulation (9 papers), Receptor Mechanisms and Signaling (7 papers) and Cholinesterase and Neurodegenerative Diseases (7 papers). Sheryl A. McCarthy collaborates with scholars based in United States and Germany. Sheryl A. McCarthy's co-authors include Judith A. Siuciak, Douglas S. Chapin, A. Martin, Robert D. Williams, Frank S. Menniti, Christopher J. Schmidt, John F. Harms, John D. McNeish, Lorraine A. Lebel and Patricia A. Seymour and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Pharmacology and Experimental Therapeutics and Psychopharmacology.

In The Last Decade

Sheryl A. McCarthy

14 papers receiving 1.4k citations

Peers

Countries citing papers authored by Sheryl A. McCarthy

Since Specialization

Citations

This map shows the geographic impact of Sheryl A. McCarthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheryl A. McCarthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheryl A. McCarthy more than expected).

Fields of papers citing papers by Sheryl A. McCarthy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheryl A. McCarthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheryl A. McCarthy. The network helps show where Sheryl A. McCarthy may publish in the future.

Co-authorship network of co-authors of Sheryl A. McCarthy

This figure shows the co-authorship network connecting the top 25 collaborators of Sheryl A. McCarthy. A scholar is included among the top collaborators of Sheryl A. McCarthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheryl A. McCarthy. Sheryl A. McCarthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures 2015 ·Neuropharmacology ·(unknown), Baher A. Ibrahim, Sheryl A. McCarthy, Kevin B. Baker, Michy P. Kelly	29
2	3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization 2009 ·Bioorganic & Medicinal Chemistry Letters ·Allen J. Duplantier, Ivan Efremov, (unknown), Angela C. Doran, Alan H. Ganong, (unknown), (unknown), Kenneth G. Kraus, John T. Lazzaro, (unknown), Noha Maklad, Sheryl A. McCarthy, Theresa J. O’Sullivan, Bruce N. Rogers, Judith A. Siuciak, Douglas K. Spracklin, Lei Zhang	21
3	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia 2008 ·Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt, Douglas S. Chapin, (unknown), Michael L. Corman, Mihály Hajós, John F. Harms, William E. Hoffman, Lorraine A. Lebel, Sheryl A. McCarthy, (unknown), (unknown), Mark J. Majchrzak, Andres D. Ramirez, Karl T. Schmidt, P A Seymour, Judith A. Siuciak, F. David Tingley, Robert D. Williams, Patrick R. Verhoest, Frank S. Menniti	238
4	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme 2007 ·Psychopharmacology ·Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, A. Martin	92
5	Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme 2007 ·Psychopharmacology ·Judith A. Siuciak, Douglas S. Chapin, Sheryl A. McCarthy, A. Martin	73
6	Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background 2007 ·Neuropharmacology ·Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, A. Martin, John F. Harms, Christopher J. Schmidt	49
7	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme 2007 ·Neuropharmacology ·Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, Tracy M. Reed, Charles V. Vorhees, David R. Repaske	48
8	Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits 2007 ·Psychopharmacology ·Judith A. Siuciak, Sheryl A. McCarthy, A. Martin, Douglas S. Chapin, Jeffrey L. Stock, (unknown), (unknown), (unknown), Stafford McLean	43
9	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis 2006 ·Neuropharmacology ·Judith A. Siuciak, Douglas S. Chapin, John F. Harms, Lorraine A. Lebel, Sheryl A. McCarthy, Leslie K. Chambers, Alka Shrikhande, Stephen K.-F. Wong, Frank S. Menniti, Christopher J. Schmidt	226
10	Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function 2006 ·Neuropharmacology ·Judith A. Siuciak, Sheryl A. McCarthy, Douglas S. Chapin, (unknown), Larry C. James, Robert D. Williams, Jeffrey L. Stock, John D. McNeish, Christine A. Strick, Frank S. Menniti, Christopher J. Schmidt	196
11	CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity 2006 ·Neuropharmacology ·Judith A. Siuciak, Douglas S. Chapin, Sheryl A. McCarthy, Victor Guanowsky, Janice A. Brown, (unknown), Ravi B. Marala, Terrell A. Patterson, Patricia A. Seymour, Andrew G. Swick, Philip A. Iredale	113
12	PDE10A knockout mice: Behavioral characterization and effects of papaverine, a PDE10A inhibitor 2003 ·Schizophrenia Research ·Judith A. Siuciak, Douglas S. Chapin, Sheryl A. McCarthy, John F. Harms, (unknown), Alka Shrikhande, (unknown), Robert D. Williams, Frank S. Menniti, L James, Christine A. Strick, Jeffrey L. Stock, John McNeish	1
13	The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic” 2003 ·Schizophrenia Research ·(unknown), Douglas S. Chapin, Sheryl A. McCarthy, (unknown), John F. Harms, Alka Shrikhande, Leslie K. Chambers, (unknown), Judith A. Siuciak	4
14	Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 2000 ·Proceedings of the National Academy of Sciences ·Michael K. Ahlijanian, Nestor X. Barrezueta, Robert D. Williams, Amy Jakowski, (unknown), Sheryl A. McCarthy, Timothy Coskran, Anthony Carlo, Patricia A. Seymour, John E. Burkhardt, Robert B. Nelson, John D. McNeish	282

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact